Immune Design Corp (IMDZ) Expected to Post Earnings of -$0.33 Per Share

Wall Street brokerages forecast that Immune Design Corp (NASDAQ:IMDZ) will post earnings of ($0.33) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Immune Design’s earnings, with estimates ranging from ($0.39) to ($0.24). Immune Design posted earnings per share of ($0.52) in the same quarter last year, which would suggest a positive year over year growth rate of 36.5%. The firm is scheduled to issue its next earnings results on Wednesday, November 7th.

According to Zacks, analysts expect that Immune Design will report full-year earnings of ($1.25) per share for the current fiscal year, with EPS estimates ranging from ($1.35) to ($1.05). For the next year, analysts anticipate that the business will post earnings of ($1.25) per share, with EPS estimates ranging from ($1.59) to ($0.93). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for Immune Design.

Immune Design (NASDAQ:IMDZ) last announced its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.01. Immune Design had a negative net margin of 2,324.21% and a negative return on equity of 46.95%. The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.64 million.

A number of analysts have recently commented on the stock. HC Wainwright assumed coverage on shares of Immune Design in a report on Wednesday, August 29th. They set a “buy” rating and a $11.00 target price on the stock. Zacks Investment Research cut shares of Immune Design from a “buy” rating to a “sell” rating in a report on Wednesday, July 4th. Finally, ValuEngine upgraded shares of Immune Design from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. Immune Design presently has a consensus rating of “Hold” and an average target price of $8.50.

Shares of IMDZ stock traded up $0.02 during mid-day trading on Tuesday, reaching $3.40. 74,100 shares of the company’s stock traded hands, compared to its average volume of 337,856. Immune Design has a 12 month low of $2.80 and a 12 month high of $11.10. The stock has a market cap of $168.58 million, a PE ratio of -1.97 and a beta of 1.77.

Institutional investors and hedge funds have recently bought and sold shares of the company. DRW Securities LLC raised its position in shares of Immune Design by 117.6% in the 1st quarter. DRW Securities LLC now owns 37,000 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 20,000 shares during the last quarter. Tiverton Asset Management LLC purchased a new position in shares of Immune Design in the 2nd quarter worth about $176,000. Essex Investment Management Co. LLC purchased a new position in shares of Immune Design in the 2nd quarter worth about $192,000. Bank of America Corp DE raised its position in shares of Immune Design by 231.9% in the 2nd quarter. Bank of America Corp DE now owns 46,754 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 32,669 shares during the last quarter. Finally, Alps Advisors Inc. purchased a new position in shares of Immune Design in the 2nd quarter worth about $318,000. 49.41% of the stock is owned by hedge funds and other institutional investors.

Immune Design Company Profile

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

Further Reading: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Immune Design (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply